Article Link: FDA Approves Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis &#...
FDA Approves Saxenda (liraglutide) for the Treatment of Obesity in Adolescents Aged 12-17
Article Link: FDA Approves Saxenda (liraglutide) for the Treatment of Obesity in Adolescents Aged 12-17 PLAINSBORO, N.J., Dec. 4, 2020 /P...
FDA Approves Orladeyo (berotralstat) as the First Oral, Once-Daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
Article Link: FDA Approves Orladeyo (berotralstat) as the First Oral, Once-Daily Therapy to Prevent Attacks in Hereditary Angioedema Patients &#...
FDA Approves Gallium 68 PSMA-11 as the First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer
Article Link: FDA Approves Gallium 68 PSMA-11 as the First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer December 01, 2020 ...
Genentech Announces FDA Approval of Xolair (omalizumab) for Adults with Nasal Polyps
Article Link: Genentech Announces FDA Approval of Xolair (omalizumab) for Adults with Nasal Polyps South San Francisco, CA — Decemb...
FDA Approves Hetlioz (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome
Article Link: FDA Approves Hetlioz (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome WASHINGTON, ...
Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers
Article Link: Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyr...
FDA Approves Imcivree (setmelanotide) for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency
Article Link: FDA Approves Imcivree (setmelanotide) for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency ...
FDA Approves Danyelza (naxitamab-gqgk) for the Treatment of Neuroblastoma
Article Link: FDA Approves Danyelza (naxitamab-gqgk) for the Treatment of Neuroblastoma NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) — ...
FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1
Article Link: FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 CAMBRIDGE, Mass.–(BUSINESS WIRE)...
